INSTITUTO NACIONAL DE PSIQUIATRIA RAMON DE LA FUENTE MUNIZ
发明人:
ANTON PALMA, BENITO,LEFF GELMAN, PHILIPPE
申请号：
ES05761917
公开号：
ES2435769T3
申请日:
2005.07.05
申请国别(地区):
ES
年份:
2013
代理人:
摘要：
structural design, preparation methods and chemical composition of two structural formulations of bivalent vaccines against morphine-heroin addiction (morphine-6-hemiscuccinil-EDC-TFCS-tetanus toxoid and reveals 3-0-carboxymethylmorphine-EDC-TFCS- tetanus toxoid), suitable for use in vaccination elhumano, which are capable of inducing the synthesis of polyclonal antibodies against this addictive opioid and against its análogoestructural heroin, through administration live repeated in, in a vaccination scheme active in preclinical studies in the same animal. the paradigm of active vaccination with these immunogens, the soncapaces which induce an immune response humoral high titers of serum antibodies specific long-term consolidated with memoriaa against these two drugs is also revealed. Complementarily, it is also revealed that these chemical compositions inmunógenostienen capabilities confer immunoprotection against laadicción effective morphine and its structural congener highly addictive, heroin, in the pharmacological model of addictive autoadministraciónintravenosa of these opiate in the rodent. Finally, the potential therapeutic implications of further use of these immunoconjugates in active vaccination schemes for the treatment of addiction to these drugs in elhumano discussed.Se revela el diseño estructural, métodos de preparación y composición química de dos formulaciones estructurales de vacunas bivalentes contra la adicción a morfina-heroína (morfina-6-hemiscuccinil-EDC-TFCS-toxoide tetánico y 3-0-carboximetilmorfina-EDC-TFCS-toxoide tetánico), adecuados para su empleo en la vacunación en elhumano, los cuales son capaces de inducir la síntesis de anticuerpos policlonales contra este opiáceo adictivo y contra su análogoestructural la heroína, a través de su administración repetida in vivo, en un esquema de vacunación activa en estudios de fase preclínica en el modelo animal del roedor. También se revela el paradigma de vacunación activa con estos inmunógeno
